CLINICAL DATA REPORTS 2006 REVENUE INCREASED 22% TO $68.8
MIL.
Reflecting substantial acquisitions in fiscal year 2006, Clinical
Data, Inc. (NASDAQ: CLDA), Newton, Mass., has reported financial results
for the fiscal year ended March 31, 2006.
Total revenue . . .
CHAD THERAPEUTICS REPORTS 4TH QTR NET LOSS OF $460,000.
CHAD Therapeutics, Inc. (AMEX:CTU), Chatsworth, Calif., has
reported financial results for the fourth quarter and fiscal 2006, and
provided an update on the company's evaluation of . . .
BIOMET REPORTS 4TH QTR NET SALES INCREASED 7% TO
$539,892,000.
Biomet, Inc. (NASDAQ:BMET), Warsaw, Ind., has announced that its
board of directors declared a cash dividend of $0.30 per share, payable
July 21, 2006, to shareholders of record at the close of . . .
ENZO BIOCHEM REPORTS $3.4 MIL NET LOSS FOR 3RD QTR
FISCAL'06.
Biochem, Inc. (NYSE:ENZ), Farmingdale, N.J., a leading
biotechnology company specializing in gene identification and genetic
and immune regulation technologies for diagnostic and . . .
CANTEL MEDICAL REPORTS 20% INCREASE IN 3RD QTR NET
INCOME.
Cantel Medicl Corp. (NYSE:CMN) has reported a 20% increase in net
income to $4,583,000, or $0.28 per diluted share, on a 29% increase in
sales to $65,358,000 for its third quarter ended April 30, . . .
TARGACEPT REPORTS NET LOSS OF 5.5 MIL FOR FIRST QTR 2006.
Targacept, Inc. (Nasdaq: TRGT), Winston-Salem, N.C., a
clinical-stage biopharmaceutical company focused on a new class of drugs
that selectively target neuronal nicotinic receptors, or NNRs, to . . .
SURMODICS REPORTS 2ND QTR '06 RECORD REVENUE OF $17.7
MIL.
SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface
modification and drug delivery technologies to the healthcare industry,
has reported financial results for the second fiscal quarter . . .
MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2
MIL.
MGI PHARMA, INC. (NASDAQ:MOGN), an oncology- and acute care-
focused biopharmaceutical company, Minneapolis, Minn., has reported
total revenue for first quarter 2006 of $78.2 million. GAAP net loss . . .
BARD REPORTS FIRST QTR 2006 NET SALES OF $467.5 MILLION.(C.R.
Bard Inc.)
C. R. Bard, Inc. (NYSE: BCR), Murray Hill, N.J., has reported 2006
first quarter financial results. First quarter 2006 net sales were
$467.5 million, an increase of 9 percent over the prior-year . . .
HANA BIOSCIENCES REPORTS 2ND QTR 2005 NET LOSS OF $president
MIL.
Hana Biosciences (OTCBB: HNAB), a South San Francisco based
biopharmaceutical company that acquires, develops, and commercializes
innovative products to advance cancer care, reported a net loss of . . .
BOVIE REPORTS 2ND QTR NET LOSS OF $118,337 IN REVENUES.(Bovie
Medical Corp.)
Bovie Medical Corporation, (Amex: BVX), Melville, N.Y., a
manufacturer and marketer of electrosurgical products, has announced its
financial results for the second quarter and six months ended June . . .
CORTEX REPORTS 2ND QTR NET LOSS OF $2,689,000.
Cortex Pharmaceuticals, Inc. (AMEX: COR), Irvine, Calif., reported
a net loss of $2,689,000 ($0.08 per share) for the quarter ended June
30, 2005, compared with a net loss of $1,314,000 ($0.05 per . . .
SPIRE REPORTS 2ND QTR 2005 NET EARNINGS OF $4,698,000.
-- Sales from operations increased 73% year to year.
-- Income from the sale of licenses was $6,320,000.
-- Earnings were $0.69 per basic share.
-- Cash is strong at $7.6 million, with no . . .
DYADIC REPORTS 2005 2ND QTR NET LOSS OF 2.3 MILLION.
Dyadic International, Inc. (AMEX:DIL), Jupiter, Fla., a
biotechnology company, has announced financial results for its second
quarter ended June 30, 2005.
Second Quarter 2005 and Subsequent . . .
SEPRACOR REPORTS 2ND QTR 2005 NET LOSS OF $7.4 MILLION.
Sepracor Inc. (Nasdaq: SEPR), Marlborough, Mass., has announced its
consolidated financial results for the second quarter of 2005. For the
three months ended June 30, 2005, Sepracor's consolidated . . .
THERAGENICS REPORTS 2ND QTR '05 NET LOSS OF $1
MILLION.
Theragenics Corporation(R) (NYSE: TGX), Buford, Geo., a provider of
brachytherapy products that include TheraSeed(R), its premier
palladium-103 prostate cancer treatment device, and wound . . .
POLYMEDICA DECLARES REGULAR QUARTERLY DIVIDEND.
PolyMedica Corporation (NASDAQ/NM: PLMD), Woburn, Mass. announced
today that its board of directors has declared a regular cash dividend
for its fiscal 2006 first quarter ended June 30, 2005, of . . .
SIMULATIONS PLUS REPORTS RECORD 3RD QTR REVENUES.
Simulations Plus, Inc. (AMEX:SLP), Lancaster, Calif., a leading
provider of ADMET absorption simulation and neural net
structure-to-property prediction software for pharmaceutical discovery
and . . .
CLINICAL DATA REPORTS RECORD FISCAL YEAR 2005 RESULTS.
Clinical Data, Inc. (NASDAQ:CLDA), Newton, Mass. has announced that
consolidated revenues and earnings for its fiscal year and fourth
quarter ended March 31, 2005. Revenues for fiscal year 2005 . . .
DUSA EXPECTS REVENUE TO REFLECT SIGNIFICANT GROWTH.
In response to current market conditions, DUSA Pharmaceuticals
(NASDAQ NMS:DUSA), Wilmington, Mass., has reported that it now expects
sales of its Levulan(R) Kerastick(R) and BLU-U(R) brand light . . .
|
|